Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CGEM vs CRMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRMD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

CRMD Overall Winner 6-Pillar Tally: CGEM 2 – 4 CRMD Matrix Metrics: CGEM 4 – 6 CRMD

As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Cullinan Therapeutics, Inc. (CGEM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CGEM carries a Unified Composite Score of 40.9/100 (SELL) at $9.03 (6.7x Forward P/E, 0.0% operating margin), whereas CRMD carries 55.5/100 (HOLD) at $4.70 (29.5x Forward P/E, 41.0% operating margin).

  • Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. CGEM 40.9/100 SELL) and 1.22β · 103% Vol risk profile, whereas CGEM leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CGEM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.7); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CGEM vs CRMD
CGEM NASDAQ
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.03
-4.95% 1D
Market Cap $667.4M
TTM Revenue N/A
Forward P/E 6.7x
Beta / 30D Vol 1.66β · 106% Vol
Unified Composite Score
40.9 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.3%), weak momentum, RSI 26
RSI-14: 25.7 · SMA20: $12.89 · SMA50: $15.36
CRMD NASDAQ Head-to-Head Winner
CorMedix Inc.
Pharmaceutical Preparations
$4.70
-2.59% 1D
Market Cap $370.6M
TTM Revenue $1.01B
Forward P/E 29.5x
Beta / 30D Vol 1.22β · 103% Vol
Unified Composite Score
55.5 / 100 HOLD
Tech 60.0 Fund 62.0 Flow 70.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.1%), weak momentum, RSI 27
RSI-14: 26.8 · SMA20: $6.18 · SMA50: $7.04

6-Pillar Scorecard Institutional Category Breakdown (CGEM 2 – 4 CRMD)

Columns: Metric · CGEM · CRMD
1. Valuation Multiples CRMD
Forward P/E 6.7x 29.5x
Trailing P/E 6.7x 2.4x
PEG Ratio N/M 3.32x
EV / Revenue N/M N/M
2. Growth & Scale CGEM
Revenue Growth (YoY) +0.0% -47.7%
Earnings Growth (YoY) +0.0% +6.7%
TTM Revenue (USD) N/A $1.01B
Market Cap $667.4M $370.6M
3. Profitability & Quality CRMD
Gross Margin N/A 87.4%
Operating Margin 0.0% 41.0%
Net Profit Margin 0.0% 15.5%
Return on Equity (ROE) -55.5% 15.3%
4. Balance Sheet & Cash Flow CRMD
Cash Generation (TTM) N/A $755M
Cash Flow Margin N/A 74.6%
Net Cash / Leverage $4.33 Book/Sh · -55.5% ROE $514M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CGEM
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 124.5% (9th %ile) 53.2% (22nd %ile)
Put/Call OI Skew N/A 2.32x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat CRMD
OpEx & R&D Intensity N/A 46.4% of Rev ($469M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CGEM (4) vs CRMD (6)
Institutional Metric CGEM CRMD Criterion Row Edge
Market Capitalization
Scale
$667.4M $370.6M Larger Scale CGEM
Trailing P/E Ratio
Valuation
6.7x 2.4x Lower Multiple CRMD
Forward P/E Ratio
Valuation
6.7x 29.5x Lower Multiple CGEM
Revenue Growth (YoY)
Growth
+0.0% -47.7% Higher Growth CGEM
Operating Margin (TTM)
Profitability
0.0% 41.0% Higher Margin CRMD
Net Profit Margin
Profitability
0.0% 15.5% Higher Margin CRMD
Return on Equity (ROE)
Capital Efficiency
-55.5% 15.3% Higher ROE CRMD
52-Week Range Position
Momentum
7% ($8–$23) 1% ($5–$13) Stronger Trend CGEM
Beta / 30D Volatility
Risk Regime
1.66β · 106% Vol 1.22β · 103% Vol Lower Realized Risk CRMD
Unified Institutional Score
Composite Signal
40.9 / 100 (SELL) 55.5 / 100 (HOLD) Higher Composite CRMD
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.01B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 87.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 3.32x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($4.33 Book/Sh · -55.5% ROE) $755M ($514M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGEM +0.97 pp
CGEM: -35.41% · CRMD: -36.38%
3M Horizon CRMD +15.01 pp
CGEM: -59.9% · CRMD: -44.89%
6M Horizon CGEM +3.66 pp
CGEM: -36.3% · CRMD: -39.96%
1Y Horizon CGEM +63.84 pp
CGEM: +5.61% · CRMD: -58.23%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGEM vs CRMD. Trailing 12-month operating profitability (CGEM 0.0% vs CRMD 41.0%) and valuation multiples (CGEM 6.7x vs CRMD 29.5x Forward P/E) are benchmarked directly in Pillar 4 below.

CGEM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-55.5% · 6.7x
CRMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.01B
Gross Margin87.4%
Op. Margin41.0%
ROE / Fwd P/E15.3% · 29.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CGEM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 124.5%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CGEM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRMD BREAKDOWN
110d in phase · OBV DISTRIBUTION
Current IV 53.2%
IV Percentile 22nd %ile
Put/Call OI Skew 2.32x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CGEM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $667.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CRMD Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $370.6M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment 46.4% of Rev ($469M)
90D Engineering Disclosures 0 Published

Investor FAQ CGEM vs CRMD Key Questions & Quantitative Answers

As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Cullinan Therapeutics, Inc. (CGEM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CGEM carries a Unified Composite Score of 40.9/100 (SELL) at $9.03 (6.7x Forward P/E, 0.0% operating margin), whereas CRMD carries 55.5/100 (HOLD) at $4.70 (29.5x Forward P/E, 41.0% operating margin). Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. CGEM 40.9/100 SELL) and 1.22β · 103% Vol risk profile, whereas CGEM leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CGEM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.7); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGEM leads the Growth & Scale pillar: CGEM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CRMD at -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.01B TTM revenue (87.4% gross margin, 41.0% operating margin). On trailing 12-month operating scale, CGEM generates N/A in USD-normalized revenue versus $1.01B for CRMD. In operating R&D and SG&A reinvestment, CGEM deploys N/A (0 90-day corporate R&D disclosures) versus 46.4% of Rev ($469M) (0 disclosures) for CRMD.

CRMD screens cheaper on headline valuation multiples. CGEM trades at 6.7x Forward P/E, 6.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CRMD trades at 29.5x Forward P/E, 2.4x Trailing P/E, 3.32x PEG, and N/M EV/Revenue (74.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGEM (-55.5% ROE) versus CRMD (15.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CGEM carries 124.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.66β · 106% Vol realized risk). By comparison, CRMD carries 53.2% implied volatility (22nd %ile, Compressed (<25th %ile)), a 2.32x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.22β · 103% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.